




RealRate

PHARMACEUTICAL 2022

Spyre Therapeutics Inc
Rank 245 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Spyre Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Spyre Therapeutics Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 35% points. The greatest weakness of Spyre Therapeutics Inc is the variable Research and Development, reducing the Economic Capital Ratio by 28% points.

The company's Economic Capital Ratio, given in the ranking table, is 284%, being 8.5% points above the market average of 275%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	98,891	Assets	109,926
Cost of Goods Sold	0	Liabilities	25,985
Intangible Assets	0	Expenses	84,529
Liabilities, Current	20,144	Revenues	18,739
Liabilities, Non-Current	4,624	Stockholders Equity	83,941
Other Assets	6,486	Net Income	-65,801
Other Compr. Net Income	-31	Comprehensive Net Income	-65,816
Other Expenses	141	BaseVar	119,610
Other Liabilities	1,217	ECR before LimitedLiability	172%
Other Net Income	-11	Economic Capital Ratio	284%
Other Revenues	18,739		
Property and Equipment	4,549		
Research and Development	57,069		
Selling, General and Administrative Expense	27,319		